Related Experiment Videos
Effect of a beta 2-adrenoceptor stimulation on hyperglycemia-induced endothelial dysfunction
Armin Kabat1, Klaus Pönicke, Aida Salameh
1Institute for Pharmacology, University of Halle, Germany.
The Journal of Pharmacology and Experimental Therapeutics
|November 1, 2003
Summary
Beta(2)-adrenoceptor stimulation prevents endothelial dysfunction caused by high glucose levels. This finding suggests a potential therapeutic target for managing hyperglycemia-induced vascular complications.
Area of Science:
- Cardiovascular Biology
- Endocrinology
- Pharmacology
Background:
- Hyperglycemia is a hallmark of diabetes and contributes to endothelial dysfunction.
- Endothelial dysfunction is characterized by impaired nitric oxide (NO) bioavailability and increased vascular inflammation.
- Beta(2)-adrenoceptors are potential targets for modulating endothelial function.
Purpose of the Study:
- To determine if beta(2)-adrenoceptors are present on porcine aortic endothelial cells (PAECs).
- To investigate whether stimulating beta(2)-adrenoceptors can prevent hyperglycemia-induced endothelial dysfunction.
- To elucidate the role of beta(2)-adrenoceptor stimulation in nitric oxide release and cellular changes under hyperglycemic conditions.
Main Methods:
- PAECs were cultured and exposed to normal or high glucose concentrations, with or without salbutamol (a beta(2)-adrenoceptor agonist) and specific antagonists.
- Nitric oxide release was measured using the met-hemoglobin assay.
- Beta-adrenoceptor density and subtypes were assessed via radioligand binding assays.
- Intracellular NADH and NADPH levels were quantified using high-performance liquid chromatography.
Main Results:
- High glucose significantly reduced nitric oxide release and increased giant cell formation, indicative of endothelial dysfunction.
- Chronic salbutamol treatment prevented the impairment of nitric oxide release and reduced giant cell formation.
- ICI 118,551 (a beta(2)-antagonist) blocked the protective effects of salbutamol, while metoprolol (a beta(1)-antagonist) did not.
- NADH production increased under hyperglycemia but was normalized by salbutamol treatment.
- Radioligand binding confirmed the presence of beta(2)-adrenoceptors on PAECs.
Conclusions:
- Hyperglycemia induces endothelial dysfunction in PAECs, characterized by impaired nitric oxide release.
- Beta(2)-adrenoceptor stimulation effectively prevents hyperglycemia-induced endothelial dysfunction.
- Targeting beta(2)-adrenoceptors represents a promising therapeutic strategy for managing diabetic vascular complications.